Comment on Nuño Solinís R, et al. “Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence” - Sorbonne Université Accéder directement au contenu
Article Dans Une Revue Infectious Diseases and Therapy Année : 2017

Comment on Nuño Solinís R, et al. “Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence”

Résumé

As demonstrated in the review by Nuño Solinís et al. [4], we now have highly effective, well-tolerated, and cost-effective therapies to treat essentially anyone who is infected with HCV. With these tools, we can prevent not only hepatic but also many extrahepatic diseases caused by HCV. As such, I believe that interferon-free DAA therapy should be offered to most patients that have HCV EHMs as well as to all patients at risk of developing them. This stands out as the best approach to deal with the serious complications of chronic HCV infection and to speed the way to a world in which HCV is effectively eradicated.
Fichier principal
Vignette du fichier
s40121-017-0155-0.pdf (272.67 Ko) Télécharger le fichier
Origine : Publication financée par une institution
Loading...

Dates et versions

hal-01587364 , version 1 (14-09-2017)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Patrice Cacoub. Comment on Nuño Solinís R, et al. “Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence”. Infectious Diseases and Therapy, 2017, 6 (2), pp.297-301. ⟨10.1007/s40121-017-0155-0⟩. ⟨hal-01587364⟩
307 Consultations
175 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More